{
    "2021-05-13": [
        [
            {
                "time": "2021-05-12",
                "original_text": "A股融资融券日报：两融余额增加44.12亿元（5月12日）",
                "features": {
                    "keywords": [
                        "两融余额",
                        "增加"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "较年初少了11只百元股数量缩水",
                "features": {
                    "keywords": [
                        "百元股",
                        "数量缩水"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "股票市场"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "人民金融·创新药指数涨0.86% | 沃森生物、丽珠集团等新冠疫苗取得重要进展，智飞生物、人福医药重磅新药临近获批",
                "features": {
                    "keywords": [
                        "创新药指数",
                        "新冠疫苗",
                        "进展",
                        "新药获批"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "迈瑞医疗市值超过恒瑞医药千亿真是药不如械？",
                "features": {
                    "keywords": [
                        "迈瑞医疗",
                        "恒瑞医药",
                        "市值"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "医疗器械"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "2020医药板块分化：医疗高增中药化药承压 未名、舒泰神等医保出局后转亏",
                "features": {
                    "keywords": [
                        "医药板块",
                        "分化",
                        "医疗高增",
                        "中药化药承压",
                        "医保出局"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "西南证券----医药行业政策点评：第五批集采启动报量，持续看好创新药及相关产业链【行业研究】",
                "features": {
                    "keywords": [
                        "医药行业",
                        "政策点评",
                        "集采",
                        "创新药",
                        "产业链"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "华金证券----医药：关注人口结构变化带来的医药行业投资机会【行业研究】",
                "features": {
                    "keywords": [
                        "医药",
                        "人口结构变化",
                        "投资机会"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "万春医药普那布林上市申请拟提速；恒瑞医药艾瑞卡获批新适应证临床；海正药业达托霉素在美上市",
                "features": {
                    "keywords": [
                        "万春医药",
                        "普那布林",
                        "恒瑞医药",
                        "艾瑞卡",
                        "海正药业",
                        "达托霉素",
                        "上市"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "云南白药百亿战投上海医药 前者去年超26亿利润靠炒股实现",
                "features": {
                    "keywords": [
                        "云南白药",
                        "上海医药",
                        "战投",
                        "炒股",
                        "利润"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "股票市场"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}